vTv Therapeutics (VTVT) Cash from Financing Activities (2014 - 2025)

vTv Therapeutics has disclosed Cash from Financing Activities across 12 years of filings, most recently posting -$321000.0 for Q4 2025.

• In Q4 2025, Cash from Financing Activities changed N/A year-over-year to -$321000.0; the TTM figure through Dec 2025 stood at $77.4 million (up 47.21% YoY), while the FY2025 annual figure was $77.4 million, up 47.21% from the prior year.
• Cash from Financing Activities came in at -$321000.0 for Q4 2025 at vTv Therapeutics, down from $77.8 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $77.8 million in Q3 2025 to a low of -$321000.0 in Q4 2025.
• Average Cash from Financing Activities over 5 years is $11.5 million, with a median of $4.4 million recorded in 2022.
• The largest YoY upside for Cash from Financing Activities was 4711.72% in 2023 against a maximum downside of 107.69% in 2023.
• Over 5 years, Cash from Financing Activities stood at $266000.0 in 2021, then jumped by 1278.57% to $3.7 million in 2022, then slumped by 107.69% to -$282000.0 in 2023, then surged by 973.4% to $2.5 million in 2024, then sank by 113.03% to -$321000.0 in 2025.
• Per Business Quant data, the three most recent Cash from Financing Activities figures were -$321000.0 in Q4 2025, $77.8 million in Q3 2025, and -$42000.0 in Q2 2025.